Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BNT162B2 (LP.8.1)-ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID-19

NCT07222384 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT07222384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07222384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BNT162B2 (LP.8.1)-ADAPTED VACCINE IN CHILDREN 5 THROUGH 11 YEARS OF AGE CONSIDERED AT HIGH RISK FOR SEVERE COVID-19
Lead sponsor
BioNTech SE
Phase
Phase 3
Overall status
Completed
Start date
October 30, 2025
Completion date
July 24, 2026
Enrollment
344 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov-2 infection